Active studies of direct oral anticoagulants in cancer patients
| Medication . | Study title . | Indication . | Study design . | Estimated enrollment . | Sponsor . |
|---|---|---|---|---|---|
| Apixaban | Apixaban or dalteparin in reducing blood clots in patients with cancer related VTE | Acute VTE treatment in patients with active cancer | Open label RCT of apixaban vs dalteparin | 315 | Academic and Community Cancer Research United and the National Cancer Institute |
| Apixaban | Apixaban for the prevention of VTE in cancer patients (AVERT) | VTE prevention in high-risk ambulatory cancer patients receiving chemotherapy | Open label RCT of apixaban vs placebo | 574 | Ottawa Hospital Research Institute, Canadian Institutes of Health Research, and Bristol-Myers Squibb |
| Apixaban | Oral apixaban (Eliquis) vs ENOX (Lovenox) for thromboprophylaxis in women with suspected pelvic malignancy | VTE prevention in women undergoing gynecologic cancer surgery | Open label RCT of apixaban vs ENOX | 400 | University of Colorado, Denver and Bristol-Myers Squibb |
| Apixaban | Apixaban as treatment of venous thrombosis in patients with cancer: the CAP study (CAP) | Acute VTE treatment in patients with active cancer | Open label study of apixaban | 300 | University Hospital, Akershus |
| Apixaban | Evaluation of the use of apixaban in prevention of thromboembolic disease in patients with myeloma treated with iMiDs (MYELAXAT) | VTE prevention in myeloma patients | Open label study of apixaban | 105 | University Hospital, Grenoble, and Celgene Corporation |
| Edoxaban | Hokusai VTE-Cancer study | VTE treatment in patients with active cancer | Open label RCT of edoxaban vs dalteparin | 1000 | Daiichi Sankyo Inc. |
| Rivaroxaban | Rivaroxaban for the prevention of VTE in Asian patients with cancer | Acute VTE treatment in patients with active cancer | Open label study of rivaroxaban | 127 | Seoul National University Hospital and the Korean Society of Hematology Thrombosis Working Party |
| Rivaroxaban | Rivaroxaban in the treatment of VTE in cancer patients (CONKO_011) | Acute VTE treatment in patients with active cancer | Open label RCT of rivaroxaban vs LMWH | 450 | AIO-Studien-gGmbH, Charite University, Berlin, Germany, and Bayer |
| Rivaroxaban | A study to evaluate the efficacy and safety of rivaroxaban VTE prophylaxis in ambulatory cancer participants | VTE prevention in high-risk ambulatory cancer patients receiving chemotherapy | Open label RCT of rivaroxaban vs placebo | 700 | Janssen Research and Development, LLC, and Bayer |
| Medication . | Study title . | Indication . | Study design . | Estimated enrollment . | Sponsor . |
|---|---|---|---|---|---|
| Apixaban | Apixaban or dalteparin in reducing blood clots in patients with cancer related VTE | Acute VTE treatment in patients with active cancer | Open label RCT of apixaban vs dalteparin | 315 | Academic and Community Cancer Research United and the National Cancer Institute |
| Apixaban | Apixaban for the prevention of VTE in cancer patients (AVERT) | VTE prevention in high-risk ambulatory cancer patients receiving chemotherapy | Open label RCT of apixaban vs placebo | 574 | Ottawa Hospital Research Institute, Canadian Institutes of Health Research, and Bristol-Myers Squibb |
| Apixaban | Oral apixaban (Eliquis) vs ENOX (Lovenox) for thromboprophylaxis in women with suspected pelvic malignancy | VTE prevention in women undergoing gynecologic cancer surgery | Open label RCT of apixaban vs ENOX | 400 | University of Colorado, Denver and Bristol-Myers Squibb |
| Apixaban | Apixaban as treatment of venous thrombosis in patients with cancer: the CAP study (CAP) | Acute VTE treatment in patients with active cancer | Open label study of apixaban | 300 | University Hospital, Akershus |
| Apixaban | Evaluation of the use of apixaban in prevention of thromboembolic disease in patients with myeloma treated with iMiDs (MYELAXAT) | VTE prevention in myeloma patients | Open label study of apixaban | 105 | University Hospital, Grenoble, and Celgene Corporation |
| Edoxaban | Hokusai VTE-Cancer study | VTE treatment in patients with active cancer | Open label RCT of edoxaban vs dalteparin | 1000 | Daiichi Sankyo Inc. |
| Rivaroxaban | Rivaroxaban for the prevention of VTE in Asian patients with cancer | Acute VTE treatment in patients with active cancer | Open label study of rivaroxaban | 127 | Seoul National University Hospital and the Korean Society of Hematology Thrombosis Working Party |
| Rivaroxaban | Rivaroxaban in the treatment of VTE in cancer patients (CONKO_011) | Acute VTE treatment in patients with active cancer | Open label RCT of rivaroxaban vs LMWH | 450 | AIO-Studien-gGmbH, Charite University, Berlin, Germany, and Bayer |
| Rivaroxaban | A study to evaluate the efficacy and safety of rivaroxaban VTE prophylaxis in ambulatory cancer participants | VTE prevention in high-risk ambulatory cancer patients receiving chemotherapy | Open label RCT of rivaroxaban vs placebo | 700 | Janssen Research and Development, LLC, and Bayer |
Studies listed as actively enrolling patients as of June 12, 2016 on ClinicalTrials.gov.
iMiDs, immunomodulatory drugs; RCT, randomized controlled trial.